FK506:90年代の免疫抑制剤?
1Department of Medicine and Therapeutics, University of Aberdeen Medical School, UK.
Lancet (London, England)
|January 5, 1991
まとめ
強力な抗T細胞剤である新型免疫抑制剤FK 506は,肝臓移植患者の治療において有望であることが示されています. 臨床試験によると,FK 506は,シクロスポリンに比べて,よりよいリスク/利益プロファイルを提供している.
科学分野:
- 免疫学 免疫学とは
- 薬理学 薬理学とは
- 移植医療 移植医療について
背景:
- FK 506は新しいマクロリド免疫抑制薬である.
- 強力で選択的な抗T細胞剤として機能します.
- その作用のメカニズムは,サイクロスポリンと同じです.
研究 の 目的:
- 肝アロ移植を受けた患者におけるFK506の有効性と安全性を評価する.
- FK 506とサイクロスポリンとのリスク/利益比を比較する.
- 様々な移植環境でのFK 506のより広範な臨床評価を容易にするため.
主な方法:
- 肝臓アロ移植を受けた患者で臨床試験が行われました.
- シクロスポリンとの比較分析が行われました.
- 現在,欧州と北米で多センター,将来性,制御試験が進行中です.
主要な成果:
- 肝臓移植を受けた患者の臨床試験では,シクロスポリンと比較してFK 506の好ましいリスク/利益比が示されました.
- FK 506は,強力で選択的なT細胞阻害を示す.
- 進行中の試験は,複数の移植タイプにわたってFK 506の評価を拡大しています.
結論:
- FK 506は,臓器移植のための免疫抑制療法における重要な進歩を表しています.
- この薬は,肝臓移植における患者の治療結果を改善する可能性を秘めている.
- 多様な移植集団における有効性と安全性を確認するために,さらなる広範な臨床試験が不可欠です.
さらに関連する動画
11:21Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity
Published on: March 12, 2015
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
関連する概念動画
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...